Proactive - Interviews for investors

Team Internet Group's CFO, William "Billy" Green, and Head of Investor Relations, Martin Surzyn, presented key insights into the company's business strategy and financial performance at the Proactive One2One Investor Forum.

The company specialises in online marketing, leveraging social media platforms to connect consumers with relevant advertisements, making up 80% of their revenue. They utilise AI to refine consumer interests, enhancing ad targeting effectiveness.

The discussion highlighted the company's adaptation to the evolving digital landscape, emphasising the importance of social media and data privacy trends. They reported a robust growth in their main product, Tonic, contributing to 67% of revenue, alongside their domain procurement and distribution business.

Financially, Team Internet Group celebrated a 15% gross revenue growth in 2023, despite the challenging market conditions that have seen fluctuating consumer volumes and click prices. The company achieved 7% net revenue growth and an increase in adjusted EBITDA, showcasing efficient cost management and profitability.

The executives underlined the company's strategic rebranding from CentralNic Group to better reflect its focus on digital marketing. They also projected continued growth, particularly in the online presence segment, which saw a surprising 16% growth in 2023.

Looking ahead, Team Internet aims for sustained revenue growth, capitalising on market opportunities such as the U.S. presidential election's positive impact on advertising. Despite an increase in net debt due to strategic choices, including shareholder returns and share buybacks, the company remains confident in its financial strategy and operational efficiency.

#ProactiveInvestors #TeamInternetGroup #OnlineMarketing #DigitalAdvertising #SocialMediaMarketing #AIAdvertising #FinancialPerformance #InvestorForum #AdvertisingTechnology #DataPrivacy #DomainRegistration #GrowthStrategy #MarketTrends #EconomicImpact #ShareholderValue #USPresidentialElection #NetDebtManagement #RevenueGrowth #EBITDAGrowth #ConsumerTrends #TechInvesting #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Clearmind Medicine Inc CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the company: the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA). This latest patent approval solidifies Clearmind's patent protection for its flagship molecule and further establishes its extensive intellectual property (IP) protection in the psychedelic space.

Clearmind's IP portfolio now encompasses fifteen utility patent families, including patents and applications with method of use and composition of matter claims. This includes 24 pending patent applications and 27 granted patents in key jurisdictions such as the US, Europe, China, and India. The company's robust IP portfolio positions it as a leader in the development of innovative treatments in the psychedelic field.

Dr. Zuloff-Shani provided insights into Clearmind's flagship molecule, MEAI, which has shown promise in reducing the desire to consume alcoholic beverages while inducing a slight euphoric, alcohol-like experience. This treatment targets Alcohol Use Disorder, a prevalent condition characterized by an individual's inability to control their alcohol consumption despite negative consequences. MEAI also holds potential in addressing binge drinking, offering hope for individuals struggling with this harmful addiction.

Clearmind plans to commence clinical trials for alcohol use disorder, expand their IP portfolio, and explore M E's potential in treating obesity. With collaborations with esteemed institutions like Johns Hopkins and Yale, Clearmind aims to revolutionize addiction treatment and offer innovative solutions to societal challenges. Stay tuned for their exciting developments in 2024.

#proctiveinvestors #clearmindmedicineinc #nasdaq #cmnd #cse #cmnd

#AddictionTreatment, #BingeBehavior, #Pharmaceuticals, #MentalHealth, #Innovation, #HealthTech, #ClinicalTrials, #SubstituteApp, #Alcoholism, #Obesity, #PsychedelicTherapy, #MedicalResearch, #DrugDevelopment, #IPPortfolio, #ChinaPatent, #JohnsHopkinsCollaboration, #YaleUniversity, #HealthcareInnovation, #MolecularScience, #Biotech, #MentalWellness, #BehavioralHealth, #MedicalBreakthroughs#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Wishpond Technologies CEO Ali Tajskandar joined Steve Darling from Proactive to unveil an exciting development: the beta launch of Wishpond's AI-powered sales platform, SalesCloser AI. This innovative platform is poised to revolutionize sales processes by delivering personalized, round-the-clock sales calls and product demos without the need for human intervention. With several hundred businesses already signed up for the SalesCloser Beta program, Wishpond Technologies invites businesses of all sizes and industries to continue registering for the program.

During the interview, Tajskandar emphasized that SalesCloser AI addresses the critical challenge of accelerating sales and scaling businesses of all sizes and industries in a cost-effective manner. Acting as a constantly learning sales agent, SalesCloser AI tirelessly works to close deals 24x7, enabling businesses to maximize their sales potential.

Additionally, Wishpond Technologies announced that SalesCloser would be led by Kevin Ho, Wishpond’s General Manager of Brax and Viral Loops. Ho, who joined Wishpond in 2015, boasts a wealth of experience across various senior roles in sales, marketing, and customer success. Notably, as Vice President of Sales and Marketing, he spearheaded lead generation, strategic partnerships, and public relations for the company.

The beta launch of SalesCloser AI represents a significant milestone for Wishpond Technologies, underlining the company's commitment to driving innovation and delivering cutting-edge solutions to its clients. With SalesCloser AI poised to transform sales processes and empower businesses to achieve greater efficiency and success, Wishpond Technologies is well-positioned to lead the way in the rapidly evolving landscape of sales technology. Stay tuned for further updates as SalesCloser AI continues to gain traction and make waves in the industry.

#proactiveinvestors #wishpondltd #tsxv #wish #otcqx #wpndf

#SalesCloser #AI #SalesDemos #Business #Technology #Innovation #SaaS #Entrepreneurship #Marketing #Sales #SmallBusiness #Startups #DigitalMarketing #ArtificialIntelligence #GlobalMarket #BetaProgram #ProductLaunch #Multilingual #Efficiency #Automation #CustomerEngagement #DigitalTransformation #OnlineSales #DemoAutomation

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Jeremy Sturgess-Smith, Finance Director of Ananda Developments Plc, presented at the Proactive One2One Investor Forum, highlighting the company's shift towards addressing chronic pain through medical cannabis.

Since its IPO in 2018, Ananda has evolved from a broader investment focus to specialise in conditions like endometriosis, chemotherapy-induced pain, and fibromyalgia. Sturgess-Smith emphasised the significant potential, noting the £5 billion annual NHS expenditure on musculoskeletal pain alone. Ananda aims to offer better treatments for chronic pain, a notoriously difficult condition to manage, by leveraging medical cannabis, which has shown promising results without the adverse effects of traditional therapies.

In 2018, the UK legalised prescribed medical cannabis for specific conditions, sparking industry development. Ananda, seizing this opportunity, has initiated government-funded clinical trials for non-THC cannabis-based formulations targeting endometriosis and chemotherapy-induced peripheral neuropathy. These trials, conducted by leading experts at Edinburgh University, mark a crucial step towards NHS adoption.

Ananda's strategy also includes utilising its cultivation facility for research, with plans for commercial production once economically viable.

The company's unique position is supported by a strong board with healthcare and pharmacology expertise, aiming to create a sustainable competitive advantage through its intellectual property and patient-focused approach.

Ananda's commitment to innovation in medical cannabis is poised to benefit patients with chronic pain, aligning shareholder interests with significant healthcare advancements.

*One point to note – the treatment of endometriosis via surgery doesn’t necessarily mean hysterectomy – it can just mean the surgery for removal of lesions.

#ProactiveInvestors #AnandaDevelopments #MedicalCannabis #ChronicPainRelief #ClinicalTrials #CannabisResearch #EndometriosisTreatment #FibromyalgiaRelief #HealthcareInnovation #UKCannabis #CannabisMedicine #Pharmaceuticals #NHS #InvestorForum #CannabisInvestment #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FTSE 100 enjoyed gains this morning after UK inflation data came in better than expected.

Prices rose by 4% in January, as per the ONS, which was in line with December’s inflation rate but below market expectations for a 4.2% jump.

Among those reporting were water firms United Utilities and Severn Trent, which both climbed after backing guidance for the year, despite an influx of storms in recent months.

Dunelm also offered up results, with these showing a 4.8% rise in interim pre-tax profit to £123 million, even as the retailer noted “more difficult” trading conditions.

And finally, Coca-Cola’s London-listed shares soared after the drinks firm hailed record profits for the year to December.

#proactiveinvestors #marketreport #ONS #inflation #UnitedUtilities #SevernTrent #Dunelm #Cocacola #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS).

Phillips highlighted the significance of SNT-5505 in addressing MDS, a complex condition, underscoring the drug's potential impact on patient care.

The company is collaborating with several partners in a strategic move that fosters local partnerships to advance the research.

From a commercial standpoint, this development represents a pivotal advancement for Syntara, as it embarks on its fourth concurrent Phase 2 study, balancing the demands of cash flow and timelines effectively.

Looking ahead, Phillips hinted at an ambitious roadmap for Syntara, signalling a period of intense activity and innovation as the company continues to explore the therapeutic potential of SNT-5505 and its impact on treating challenging medical conditions.

#ProactiveInvestors #Syntara #ASX #SNT5505 #biotech

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poseidon Nickel Ltd (ASX:POS) CEO Craig Jones sits down with Proactive’s Jonathan Jackson to discuss the identification of two new highly prospective nickel sulphide targets at WIndarra Project that bring the total to six so far. POS is particularly interested in these new targets, as they are overlayed by prospective geology and supported by field mapping data as well as surface geochemistry. Jones also discusses the value of the collaborations in the region, which is helping it advance several quality greenfields nickel and lithium targets at Lake Johnston and how these collaborations have re-rated its nickel potential. Finally, Jones speaks about the work going on at Lake Johnston.

#ProactiveInvestors #PoseidonNickel #ASX #Nickel #BatteryMetals #WindarraProject

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Australian Rare Earths Ltd (ASX:AR3) CEO Travis Beinke sits down with Jonathan Jackson in the Proactive studio to explore the company's latest developments and strategic direction. Beinke offers a comprehensive overview of AR3, including its primary objectives and the geographical focus of its projects.

Bienke also speaks about recent advancements at the Koppamurra Rare Earths Project in South Australia including a drilling program and its outcomes. He elaborates on the significance of discovering high-grade intercepts and the identification of mineralisation with elevated magnet rare earth oxide (MREO) content.

Beinke touches on the importance of tenure extensions at Koppamurra, as well as exploration prospects in North Queensland, outlining how these developments bolster AR3's position in the rare earths sector. He outlines the company's exploration plans for the newly acquired tenements and shares the overarching objectives for Koppamurra.

Finally, he highlights several key investment points for potential investors.

#ProactiveInvestors #AustralianRareEarths #ASX #RareEarthElements #MagnetRareEarthOxide #CriticalMinerals

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lithium Universe CEO Alex Hanly joins Proactive’s Jonathan Jackson to discuss the company's approach to addressing the lithium conversion capacity gap in North America. Hanley speaks about its progress with metallurgical testing and the development of a lithium refinery in Quebec. He explains the strategic importance of this project, highlighting the company's ability to process spodumene from various sources, which is essential for adapting to market changes. Hanly also gives his perspective on the current state of the lithium market and the future prospects for Lithium Universe within it. Finally, Hanley gives an update on the company's progress in finalising feasibility studies for its projects.

#ProactiveInvestors #LithiumUniverse #ASX #Lithium #CriticalMinerals

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to announce a new Partnership Agreement with New York-based Sanrai International. Sanrai International, a leading medical device distribution company with a global presence, will now market and resell the Cloud DX Connected Health platform across more than 65 countries.

Kaul highlighted the significance of this partnership, emphasizing Sanrai's extensive customer and sub-distributor network, which spans Latin America, Africa, the Middle East, Asia, and beyond. The focus of this collaboration will be on addressing chronic disease management and post-surgical recovery, leveraging Cloud DX's innovative Connected Health products and services.

With the partnership in place, both Cloud DX and Sanrai aim to equalize access to innovative medical devices, particularly in the areas of chronic illness and post-surgical recovery. Kaul also mentioned that Cloud DX has already announced over $2.5 million CAD in new business in 2024, reflecting the company's continued growth and market expansion efforts.

#proactiveinvestors #clouddxinc #tsxv #cdx #otc #cdxff #medical #remotemonitoring

#CloudDX #SanraiInternational #Partnership #MedicalDevices #ConnectedHealth #ChronicDiseaseManagement #PostSurgicalRecovery #HealthcareTechnology #Innovation #GlobalHealth #Distribution #HealthcarePartnership #HealthcareIndustry #MedicalInnovation #MarketExpansion #HealthcareAccess #MedicalTechnology #HealthcareNews #GlobalPresence #InnovativeSolutions #BusinessGrowth #HealthcareNetwork #HealthTech #MedicalDevicesMarket #HealthcareInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews